Showing 11-20 of 135 results for "".
Driving Growth in the Dermatology Practice
https://practicaldermatology.com/topics/practice-management/driving-growth-in-the-dermatology-practice/18630/Robert Rullo reminds dermatologists to think beyond being just a clinician and to remember they are also running a business. He discusses key business philosophies clinicians need to be aware of and common obstacles that inhibit geometric practice growth. GenerationsGaps in Treatment and Approaches for the Pediatric Population with Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37160/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, describes gaps in treatment for children with atopic dermatitis and reasons for optimism based on ongoing clinical trials.Clinical Predictors for Distinguishing Transient Pediatric Atopic Dermatitis from Early-onset Atopic March Cases
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37159/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, talks about clinical predictors for atopic dermatitis vs early-onset atopic march.Emerging Insights into the Immunologic Subtypes of Atopic Dermatitis in Children
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37157/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, discusses new understandings regarding the immunologic subtypes of atopic dermatitis and how they should influence treatment selection.Make The Experience Unforgettable
https://practicaldermatology.com/topics/practice-management/make-the-experience-unforgettable/18583/When practices looking for ways to differentiate should focus on creating amazing experiences, says Robert Rullo. One important consideration is the person answering your phones, who needs to convey your expertise and your story.Advances in Wound Care
https://practicaldermatology.com/conferences/maui-derm-2022/maui-derm-2022-video/20040/Robert S. Kirsner, MD, PhD discusses the latest in wound healing science and resulting changes in how leading wound care experts are approaching patient care. From innovative products to greater understanding of the science, there are many options to help patients heal.Journal Club: AD's Impact on Mental Health
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-ads-impact-mental-health/28628/Practical Dermatology Editorial Board member Peter Lio, MD, chats with dermatologist Robert Sidbury, MD, MPH, about the Cureus article, "Investigation of the Impact of Atopic Dermatitis (AD) on Stress, Depression, Anxiety, and Suicidal Ideation: A Systematic Review and Meta-Analysis."Therapeutic Approaches in Pediatric Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37158/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, explains how to adjust a therapeutic approach to pediatric atopic dermatitis, particularly when considering long-term use of topical steroids or calcinPhio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Journal Club: Oral JAK Inhibitors in Moderate-to-Severe AD
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-oral-jak-inhibitors-moderate-severe-ad/24539/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a dermatologist at Seattle Children's Hospital, about nuanced differences in guideline-recommended use of oral JAK inhibitors in pediatric patients with moderate-to-severe atopic dermatitis (AD) provided in the Annals of Allergy, Asthma, and Immunol